First measurements of radon-220 diffusion in mice tumors, towards treatment planning in diffusing alpha-emitters radiation therapy

Alpha-DaRT is a new method for treating solid tumors with alpha particles, relying on the release of the alpha-emitting daughter atoms of radium-224 from sources inserted into the tumor. The most important model parameters for Alpha-DaRT dosimetry are the diffusion lengths of radon-220 and lead-212, and their estimation is essential for treatment planning. The aim of this work is to provide first experimental estimates for the diffusion length of radon-220. The diffusion length of radon-220 was estimated from autoradiography measurements of histological sections taken from 24 mice-borne subcutaneous tumors of five different types. Experiments were done in two sets: fourteen in-vivo tumors, where during the treatment the tumors were still carried by the mice with active blood supply, and ten ex-vivo tumors, where the tumors were excised before source insertion and kept in a medium at 37 degrees C with the source inside. The measured diffusion lengths of radon-220 lie in the range 0.25-0.6 mm, with no significant difference between the average values measured in in-vivo and ex-vivo tumors: 0.40 \(\pm\) 0.08 mm for in-vivo vs. 0.39 \(\pm\) 0.07 mm for ex-vivo. However, in-vivo tumors display an enhanced spread of activity 2-3 mm away from the source. This effect is not explained by the current model and is much less pronounced in ex-vivo tumors. The average measured radon-220 diffusion lengths in both in-vivo and ex-vivo tumors lie close to the upper limit of the previously estimated range of 0.2-0.4 mm. The observation that close to the source there is no apparent difference between in-vivo and ex-vivo tumors, and the good agreement with the theoretical model in this region suggest that the spread of radon-220 is predominantly diffusive in this region. The departure from the model prediction in in-vivo tumors at large radial distances may hint at potential vascular contribution.